Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
CLDX
#3995
Celldex Therapeutics, Inc
30.090
0
+0.40%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+0.40%
Aylık değişim
+14.80%
6 aylık değişim
+10.46%
Yıllık değişim
+10.46%
Önceki kapanış
29.970
0
Open
30.000
0
Bid
Ask
Low
30.000
0
High
30.090
0
Hacim
102
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
CLDX
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
39.61 M
46.74 M
47.21 M
55.9 M
66.38 M
66.57 M
—
Valuation ratios
Enterprise value
650.21 M
1.77 B
2.02 B
2.22 B
1.65 B
1.78 B
5.98 B
Price to earnings ratio
—
-23.56
-18.08
-13.84
-10.31
-6.96
-28.1
Price to sales ratio
—
0.36
0.86
0.28
0.23
1.17
2.21
Price to cash flow ratio
—
0.03
0.02
0.02
0.01
0.01
0.03
Price to book ratio
—
0
0.01
0
0
0
0
Enterprise value to EBITDA ratio
-30.59
-108.09
-91.6
-104.31
-57.79
-45.5
—
Profitability ratios
Return on assets %
0.25
0.16
0.24
0.2
0.13
0.44
0.41
Return on equity %
0.29
0.17
0.26
0.21
0.14
0.49
0.44
Return on invested capital %
483.12
711.84
937.82
1 040.56
1 165.13
2 329.78
—
Gross margin %
97.3
97.85
95.76
95.64
97.15
87.06
400
Operating margin %
854.06
1 531.78
4 889.01
2 245.27
2 778.89
18.6 K
-7.27 M
EBITDA margin %
-286.52
-351.43
-935.09
-309.79
-406.48
-2 530.81
—
Net margin %
805.88
1 516.04
3 616.25
1 331.85
1 462.49
16.75 K
-6.62 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
13.93
24.86
17.07
13.87
18.91
10.49
64.83
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.01
0.02
0.01
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1 420.57
2 211.65
2 214.7
2 450.5
3 175.83
3 176.63
EBIT per share
—
-452.83
-531.82
-502.2
-492.46
-639.56
—
EBITDA per share
—
-381.27
-470.06
-440.11
-443.12
-588.68
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9 522.98
6 503.84
8 743.17
11.26 K
7 807.25
36.22 K
Net current asset value per share
—
9 583.37
6 775.57
8 910.26
11.6 K
8 049.5
37.37 K
Tangible book value per share
—
9 150.59
6 377.2
8 296.99
11.18 K
7 527.25
35.77 K
Working capital per share
—
9 197.83
6 378.67
8 267.83
10.99 K
7 281.82
34.92 K
Book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7 936.6
37.41 K
Haberler
Celldex kronik ürtiker tedavisi için Faz 2 verilerini sundu
Celldex presents phase 2 data for chronic urticaria treatment
Celldex Therapeutics Stock Earns 88 RS Rating
Celldex Therapeutics kazancı $0,21 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Celldex Therapeutics hissesi 30,66 dolarda 52 haftalık zirve yaptı
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Stifel, Celldex Therapeutics hissesi için hedef fiyatını korudu
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Celldex, CSU tedavisi için Faz 3 kaydını planın önünde tamamladı
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Cantor Fitzgerald, Celldex’in Overweight notunu ve 67,00 dolar hedef fiyatını yineledi